Evaluating the impact of the COVID-19 pandemic on cancer screening in a central Canadian province.
Evaluating the impact of the COVID-19 pandemic on cancer screening in a central Canadian province.
复制标题
DOI：
10.1016/j.ypmed.2022.106961
复制
发表时间：
2022-03
影响因子：
5.1
通讯作者：
Lambert P
中科院分区：
文献类型：
--
作者：
Decker KM;Feely A;Bucher O;Singh H;Turner D;Lambert P
我们使用中断时间序列 (ITS) 设计和来自曼尼托巴省 2020 年 4 月至 2021 年 8 月基于人口的有组织癌症筛查项目的数据，评估了 COVID-19 对加拿大曼尼托巴省癌症筛查的影响。2020 年 6 月（2020 年 4 月至 5 月期间暂停乳腺筛查），预测值（即回归模型产生的观察数据）与预期值（即，假设未发生 COVID-19，为 COVID-19 期间生成的反事实值）筛查乳房 X 光检查的数量（比率 = 0.46，95% 置信区间 (CI) 0.28–0.64）。到 2020 年 12 月，预测的乳房 X 光检查数量与预期的筛查数量之间没有显着差异（比率 = 0.95，95% CI 0.80–1.10）。 2020 年 4 月，巴氏试验数量减少了 83%（比率 = 0.17，95% CI 0.04–0.30）。到 2021 年 1 月，预测的巴氏试验次数与预期次数之间没有显着差异（比率 = 0.93，95% CI 0.81–1.06）。 2020 年 4 月，粪便潜血检测 (FOBT) 筛查项目的数量减少了 81%（比率 = 0.19，95% CI 0.0–0.44）。到 2020 年 9 月，预测的 FOBT 数量与预期数量之间没有显着差异（比率 = 0.95，95% CI 0.65–1.24）。 2020 年 4 月至 2021 年 8 月期间估计的累计缺口（即积压）为 17,370 次乳房 X 光检查、22,086 次巴氏涂片检查和 5253 次筛查项目 FOBT。总体而言，筛查计划很快适应了 COVID-19 大流行。可能需要采取额外的策略来解决剩余的积压问题。
We evaluated the impact of COVID-19 on cancer screening in Manitoba, Canada using an interrupted time series (ITS) design and data from Manitoba's population-based, organized cancer screening programs from April 2020 to August 2021. In June 2020 (breast screening was suspended during April and May 2020), there was a 54% decrease between the predicted (i.e., observed data produced from regression models) and expected (i.e., counterfactual values produced for the COVID-19 period by assuming COVID-19 did not occur) number of screening mammograms (ratio = 0.46, 95% Confidence Interval (CI) 0.28–0.64). By December 2020, there was no significant difference between predicted and expected number of screening mammograms (ratio = 0.95, 95% CI 0.80–1.10). In April 2020, there was an 83% decrease in the number of Pap tests (ratio = 0.17, 95% CI 0.04–0.30). By January 2021, there was no significant difference between predicted and expected number of Pap tests (ratio = 0.93, 95% CI 0.81–1.06). In April 2020, there was an 81% decrease in the number of screening program fecal occult blood tests (FOBTs) (ratio = 0.19, 95% CI 0.0–0.44). By September 2020, there was no significant difference between predicted and expected number of FOBTs (ratio = 0.95, 95% CI 0.65–1.24). The estimated cumulative deficit (i.e., backlog) from April 2020 to August 2021 was 17,370 screening mammograms, 22,086 Pap tests, and 5253 screening program FOBTs. Overall, screening programs adapted quickly to the COVID-19 pandemic. Additional strategies may be needed to address remaining backlogs.
登录
查看更多内容
影响因子：
5.1
作者：
Smith, Megan A.;Burger, Emily A.;Castanon, Alejandra;de Kok, Inge M. C. M.;Hanley, Sharon J. B.;Rebolj, Matejka;Hall, Michaela T.;Jansen, Erik E. L.;Killen, James;O'Farrell, Xavier;Kim, Jane J.;Canfell, Karen
通讯作者：
Canfell, Karen
衡量199年大流行对加拿大安大略省有组织的癌症筛查和诊断随访护理的影响：一项基于人群的省级研究。
影响因子：
5.1
作者：
Walker, Meghan J;Meggetto, Olivia;Gao, Julia;Espino-Hernandez, Gabriela;Jembere, Nathaniel;Bravo, Caroline A;Rey, Michelle;Aslam, Usman;Sheppard, Amanda J;Lofters, Aisha K;Tammemagi, Martin C;Tinmouth, Jill;Kupets, Rachel;Chiarelli, Anna M;Rabeneck, Linda
通讯作者：
Rabeneck, Linda
影响因子：
3.8
作者：
Decker, Kathleen M.;Demers, Alain A.;Turner, Donna
通讯作者：
Turner, Donna
影响因子：
5.1
作者：
Jen GH;Yen AM;Hsu CY;Chiu HM;Chen SL;Chen TH
通讯作者：
Chen TH
影响因子：
3.3
作者：
Decker, Kathleen M.;Demers, Alain A.;Turner, Donna
通讯作者：
Turner, Donna